Rua’s Australian Supplier, Cann Group, Receives GMP

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



FOR PUBLIC RELEASE
NZX Limited
Wellington

Tuesday, 25 January 2022

Rua’s Australian Supplier, Cann Group, Receives GMP Certification for Southern Facility

Rua Bioscience (NZX: RUA) is pleased to share that Cann Group (ASX: CAN) has been granted a
GMP licence to manufacture therapeutic goods for its Southern facility (Southern GMP Licence)
by Australia’s Therapeutic Goods Administration (TGA).

The Southern GMP licence enables Cann to manufacture Active Pharmaceutical Ingredient (API) and
medicinal cannabis products under GMP conditions for Australian and overseas customers,
following a substantial upgrade of its facilities.

Rua Bioscience CEO, Rob Mitchell says, “this is great news for Cann Group and a critical
regulatory milestone that will enable future supply for Rua as a result of the Zalm acquisition.”

With Shareholders having approved the Rua purchase of Zalm, Rua has acquired Zalm’s third
party supply contract for GMP-grade medicinal cannabis with Cann, including exclusive supply
into New Zealand.

Cann is also in the final commissioning phase of one of Australasia’s most technologically
advanced indoor growing facilities at Mildura, Victoria, which will help Rua achieve world world-
class and globally-competitive scale. When the first stage of this facility is fully commissioned,
Cann expects to have capacity to produce 12,500kg of medicinal cannabis per annum. Cann has
the ability to increase this to 70,000kg in future stages, creating one of the largest facilities in
Australasia.

See Cann Group’s full announcement, attached.


Ends.

For more information, please contact:
Kerry Donovan
Communications Manager Rua Bioscience
Email: kerry.donovan@ruabio.com
Phone: 021 128 7689


MARKET ANNOUNCEMENT

---

Cann Group Limited
ACN 603 949 739
4 Research Avenue, Bundoora, VIC 3083 Australia
Ph: +61 3 9095 7088

ASX ANNOUNCEMENT
25 January 2022
Cann granted GMP licence for Southern facility and inspected for
Mildura GMP licence

25 January 2022 – Cann Group Limited (ASX: CAN) (Cann or the Company) is pleased to
announce that it has achieved an important regulatory milestone for the Company with the
Therapeutic Goods Administration (TGA) granting to Cann a GMP licence to manufacture
therapeutic goods for its Southern facility (Southern GMP Licence).
The Southern GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredient
(API) and medicinal cannabis products under cGMP conditions at its Southern facility for
supply in Australia and overseas. This follows a significant upgrade of that facility which was
substantially funded by the Company’s successful capital raise in July and August last year.
Dried cannabis flower products produced under the Southern GMP Licence are expected to
be available for supply to patients under the TGA’s Special Access Scheme (SAS) and
Authorised Prescriber (AP) scheme within the next few weeks.
Cann CEO, Peter Crock said: “Over the last 12 months, we have seen increasing demand for
cGMP products from both domestic and international customers and have had pre-orders in
place since late last year pending the granting of this licence. We are now able to service the
needs of those customers. The granting of this licence is also another important achievement
for Cann as we develop our integrated supply chain.”
In further regulatory updates, Cann’s Mildura facility was recently inspected by the TGA in
respect of an application for a GMP licence to manufacture therapeutic goods and to
undertake GMP testing at the Mildura site (Mildura GMP Licence).
The Mildura GMP Licence will, once granted, enable Cann to manufacture cannabis extract
(API) and Cann’s Satipharm CBD capsules. Additionally, the Mildura GMP Licence will allow
Cann to operate a GMP certified chemical, physical and microbiological laboratory for
analytical testing of cannabis dried flower and various medicinal products and excipients,
being a critical in-house capability enabling Cann to demonstrate that products meet local and
overseas regulatory requirements.

Authorised for release by the Board of Directors of Cann Group Limited.

2
For all media enquiries please contact:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au


For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouplimited.com

About Cann Group
Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating,
manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas
export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture,
develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and
cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near
Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis
and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and
medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured
medicinal cannabis products.
Learn more at: www.canngrouplimited.com | www.satipharm.com